Trial Profile
Study of the outcome of patients with lower urinary symptoms suggestive of benign prostatic hyperplasia and treated with alfuzosin 10 mg once daily for 3 months in China
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Alfuzosin (Primary)
- Indications Benign prostatic hyperplasia
- Focus Adverse reactions; Therapeutic Use
- Acronyms ALF-ONE
- Sponsors Sanofi
- 09 Oct 2006 Status change
- 10 Feb 2006 New trial record.